Preparation and application of silymarin lipid nanoparticles

A technology of lipid nanoparticles and silymarin, applied in the field of biomedicine, can solve the problems of unclear pathogenesis, achieve good brain targeting, good biodegradability, and enhance the effect of drugs

Inactive Publication Date: 2016-06-22
ZHEJIANG UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Its etiology is diverse, but the specific pathogenesis is still unclear

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation and application of silymarin lipid nanoparticles
  • Preparation and application of silymarin lipid nanoparticles
  • Preparation and application of silymarin lipid nanoparticles

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] The construction of embodiment one silymarin lipid nanoparticles

[0038] 1.1 Synthesis of silymarin lipid nanoparticles

[0039] Take 270mg of stearic acid, 90mg of medium-chain triglyceride (MCT) and 40mg of silymarin (SM), add it to 2mL of ethanol, and after heating and melting, inject it into 18mL at a constant rate under a disposable liquid containing 0.1% (mass percentage) Tween 80°C pure water, 60°C magnetic stirring for 5min, stirring at room temperature and cooling to room temperature, milky yellow, the finished product, 4°C low-temperature storage for later use, ultrasonic mixing before each use, the best ready-to-use (the finished product is unstable, put Reconstitution is required after two days).

[0040] 1.2 Size measurement of silymarin lipid nanoparticles

[0041] Take the silymarin nanoparticles synthesized above (SM SLN ) 0.5mL, dilute 10 times with deionized water, and then measure its particle size with a Zetasizer particle size measuring instrume...

Embodiment 2

[0044] Example 2 Intervention and Pharmacodynamics of Silymarin and Its Nanoparticles on the Inflammatory Response of Autism

[0045] Grouping of experimental animals: control group (C57BL / 6NJ), model group (BTBR), three administration groups: silymarin (100mg / kg) group, silymarin lipid nanoparticle (20mg / kg) group, dexamethasone (0.125mg / kg, positive drug) group, with 8 mice in each group. The method of oral administration was adopted, and the administration was continued for 30 days, once a day; the control group (con) and the model group (BTBR) were given normal saline in the same proportion of body weight.

[0046] Evaluation indicators:

[0047] A. Immunoblot detection: After 30 days of administration, the experimental mice in each group were decapitated and the brains were collected, and the brain tissue samples were collected and homogenized with lysate to lyse the tissue to extract proteins. Western-blotting method was used to examine the inflammation-related protein...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
Login to view more

Abstract

The invention provides a silymarin lipid nanoparticle. By preparing the silymarin lipid nanoparticle, combined with an autism experimental animal model, the pharmacodynamic index of the silymarin lipid nanoparticle is evaluated from the whole animal level, and it is proved that it has good The targeting of brain inflammatory lesions can enrich the drug in the inflammatory area, improve the bioavailability of the drug, and reduce the dosage of the drug. The present invention can provide a new experimental basis and idea for the clinical treatment of autism, and can be used as a more efficient and low-toxic drug-loading system in the preparation of autism inflammation intervention drugs.

Description

technical field [0001] The invention belongs to the technical field of biomedicine and relates to a targeted drug delivery system, in particular to a brain-targeted drug delivery system for treating autism, in particular to a preparation method and application of silymarin lipid nanoparticles. Background technique [0002] Autism is a generalized developmental disorder of the brain caused by disorders of nervous system development. Autism affects the development of people's social communication skills and interpersonal communication ability, and the onset often occurs before the age of 3. Its etiology is diverse, but the specific pathogenesis is still unclear. It is currently believed that the disease may be the result of a combination of environmental factors and genetic susceptibility. Studies have found that the occurrence of autism has a certain correlation with oxidative stress and inflammatory response. There is an abnormal phenomenon of inflammatory response in the ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/51A61K31/357A61P25/00
CPCA61K9/5146A61K31/357
Inventor 韩峰王平孙盟盟卢应梅杜永忠张硕高银萍王成坤
Owner ZHEJIANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap